Skip to main
LUCD

Lucid Diagnostics (LUCD) Stock Forecast & Price Target

Lucid Diagnostics (LUCD) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lucid Diagnostics is an attractive investment opportunity due to its positive developments with the EsoGuard test and potential for market expansion and partnerships. While there are risks involved, such as reimbursement and commercial execution, the company is confident in its products and expects to see significant growth in the future, with a potential market opportunity of $2 billion in the US. Investors can expect a strong return on their investment in Lucid Diagnostics and should closely monitor the company's financials and developments in the esophageal cancer market.

Bears say

Lucid Diagnostics is a medical diagnostics technology company with a negative outlook, as evidenced by its high quarterly EBITDA loss of -$13.7 million and its consistent use of cash in its operations. Despite recent success in gaining positive coverage with some of the largest commercial health plans, there remain risks to achieving positive shareholder returns due to potential balance sheet and liquidity concerns, as well as uncertainties surrounding product efficacy, regulatory approvals, and competition in the market. Additionally, the attractiveness of Lucid's current valuation may not be enough to outweigh these risks, particularly for investors with a more cautious stance on the biotech/medtech industry.

Lucid Diagnostics (LUCD) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lucid Diagnostics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lucid Diagnostics (LUCD) Forecast

Analysts have given Lucid Diagnostics (LUCD) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Lucid Diagnostics (LUCD) has a Strong Buy consensus rating as of May 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lucid Diagnostics (LUCD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.